Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RUBENS: Obicetrapib and Ezetimibe in Type 2 Diabetes and/or Metabolic Syndrome
NCT07219602Phase 3Active, not recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Dec 2025
- Primary completion
- Mar 2028
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 4
01
Overview
A Phase 3 trial of obicetrapib in hyperlipidemia, sponsored by NewAmsterdam Pharma. Started Dec 2025; status: active, not recruiting.
02
Drugs
obicetrapib
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT07219602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07219602.